The stock of Ionis Pharmaceuticals Inc (IONS) has gone down by -3.27% for the week, with a -15.92% drop in the past month and a -20.59% drop in the past quarter. The volatility ratio for the week is 9.66%, and the volatility levels for the past 30 days are 5.55% for IONS. The simple moving average for the past 20 days is -9.66% for IONS’s stock, with a -28.44% simple moving average for the past 200 days.
Is It Worth Investing in Ionis Pharmaceuticals Inc (NASDAQ: IONS) Right Now?
Moreover, the 36-month beta value for IONS is 0.27. Analysts have varying opinions on the stock, with 12 analysts rating it as a “buy,” 5 as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for IONS is 154.59M and currently, short sellers hold a 8.29% of that float. On April 10, 2025, IONS’s average trading volume was 1.74M shares.
IONS) stock’s latest price update
Ionis Pharmaceuticals Inc (NASDAQ: IONS) has seen a rise in its stock price by 8.86 in relation to its previous close of 25.51. However, the company has experienced a -3.27% decline in its stock price over the last five trading sessions. https://thefly.com reported 2025-04-07 that H.C. Wainwright initiated coverage of Ionis Pharmaceuticals with a Buy rating and $45 price target. Ionis is a commercial-stage biotech company focused on RNA-targeted therapeutics for a range of diseases, the analyst tells investors in a research note. The firm says the company has a pipeline of successful antisense oligonucleotide therapies. It sees an opportunity to own Ionis ahead of 2025 catalysts. 08 Apr 09 Apr 10 Sep
Analysts’ Opinion of IONS
Many brokerage firms have already submitted their reports for IONS stocks, with H.C. Wainwright repeating the rating for IONS by listing it as a “Buy.” The predicted price for IONS in the upcoming period, according to H.C. Wainwright is $45 based on the research report published on April 07, 2025 of the current year 2025.
Redburn Atlantic, on the other hand, stated in their research note that they expect to see IONS reach a price target of $39. The rating they have provided for IONS stocks is “Neutral” according to the report published on March 31st, 2025.
BMO Capital Markets gave a rating of “Market Perform” to IONS, setting the target price at $60 in the report published on August 02nd of the previous year.
IONS Trading at -12.35% from the 50-Day Moving Average
After a stumble in the market that brought IONS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.94% of loss for the given period.
Volatility was left at 5.55%, however, over the last 30 days, the volatility rate increased by 9.66%, as shares sank -16.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.59% lower at present.
During the last 5 trading sessions, IONS fell by -3.27%, which changed the moving average for the period of 200-days by -33.61% in comparison to the 20-day moving average, which settled at $30.74. In addition, Ionis Pharmaceuticals Inc saw -20.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IONS starting from Monia Brett P, who sale 140 shares at the price of $32.32 back on Mar 11 ’25. After this action, Monia Brett P now owns 180,980 shares of Ionis Pharmaceuticals Inc, valued at $4,525 using the latest closing price.
Monia Brett P, the Officer of Ionis Pharmaceuticals Inc, proposed sale 140 shares at $32.32 during a trade that took place back on Mar 11 ’25, which means that Monia Brett P is holding shares at $4,525 based on the most recent closing price.
Stock Fundamentals for IONS
Current profitability levels for the company are sitting at:
- -0.67 for the present operating margin
- 0.97 for the gross margin
The net margin for Ionis Pharmaceuticals Inc stands at -0.64. The total capital return value is set at -0.18. Equity return is now at value -93.03, with -15.13 for asset returns.
Based on Ionis Pharmaceuticals Inc (IONS), the company’s capital structure generated 0.71 points at debt to capital in total, while cash flow to debt ratio is standing at -0.35. The debt to equity ratio resting at 2.41. The interest coverage ratio of the stock is -5.53.
Currently, EBITDA for the company is -475.08 million with net debt to EBITDA at -3.28. When we switch over and look at the enterprise to sales, we see a ratio of 7.92. The receivables turnover for the company is 7.65for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.47.
Conclusion
To wrap up, the performance of Ionis Pharmaceuticals Inc (IONS) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
